Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sjogren's Syndrome (SS) is a chronic, female overwhelming fundamental issue of an immune system rheumatic sickness that influences the whole body. It is described by lymphocytic invasion of the exocrine viz. salivary and lacrimal glands and by surprising B-cell hyperactivity. Keratoconjunctivitis sicca (dry eye) and Stomatitis sicca (oral dryness) are the primary visual appearances of SS. The primary SS is recognized from secondary SS which happens as a piece of other immune system maladies. The secondary SS exists together particularly with fundamental lupus erythematosus (15- 36%), rheumatoid joint inflammation (20- 32%) and also restricted and progressive systemic sclerosis (11- 24%), less as often as possible with different sclerosis and immune system hepatitis and thyreoiditis. We assess changes in salivary epidermal growth factor (EGF) intensity and estimate the relationship between salivary EGF levels and the seriousness of intraoral symptoms in SS individuals. The outcomes demonstrated that the salivary EGF levels diminished with the movement of SS, and this crumbling in salivation quality and additionally, hyposalivation could imagine a vital constituent in the pathogenesis of refractory intraoral indication in SS suffering patients. A strong relationship between particular alleles of the MHC and SS improvement has been recommended. The primary hereditary examination on SS revealed a relationship amongst SS and HLA-DR3 in SS population. Subsequent reports featured the relationship amongst SS and the HLA-D locus, with a diverse distribution between primary SS and secondary SS. The motivation behind this manuscript is to give a concise survey on the molecular mechanism, effects of infectious agents and genetic factors in the etiology of Sjogren's Syndrome. Such effects are discussed independently.
 ...
PMID:From Molecular Mechanism to the Etiology of Sjogren Syndrome. 3033 43

The Food and Drug Administration has recently approved the off-label use of hydroxychloroquine (HCQ) for the treatment of coronavirus disease 2019 (COVID-19) infections. However, a recent study not only failed to demonstrate HCQ efficacy but also documented a serious side effect of COVID-19 therapy with HCQ: QT prolongation and secondary arrhythmia. HCQ has been used as an off-label drug and deemed safe and effective for the treatment of oral lesions, such as Sjogren syndrome (SS), chronic ulcerative stomatitis (CUS), and oral lichen planus (OLP). Because HCQ may be appropriately used for the off-label treatment of SS, CUS, and OLP, relevant safety concerns regarding HCQ therapy with regard to dosage, drug-to-drug interactions, and QT prolongation and secondary arrhythmia are discussed here. Because of the possibility of decreased pharmacy supplies of HCQ, replacement drugs with respect to patients with SS, CUS, and OLP being successfully treated with HCQ are also discussed.
 ...
PMID:Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19. 3265 31